Central poststroke pain (CPSP) develops commonly after stroke, which impairs the quality of life, mood, and social functioning. Current pharmacological approaches for the treatment of CPSP are not satisfactory. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique which has been recommended for the treatment of chronic CPSP. However, few studies have evaluated the analgesic effects of rTMS in patients with acute neuropathic pain after stroke.
Methods
We evaluated the analgesic effects of rTMS applied over the upper extremity area of the motor cortex (M1) in patients with acute CPSP. Forty patients were randomized to receive either rTMS (10 Hz, 2000 stimuli) (n = 20) or a sham intervention (n = 20) for 3 weeks. The Numeric Rating Scale (NRS), Short-form McGill Pain Questionnaire-2 (SF-MPQ-2, Chinese version), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HAM-D), brain-derived neurotrophic factor (BDNF) levels, and motor-evoked potentials (MEP) were analyzed at baseline, 3 days, 1 week, 2 weeks, and 3 weeks.
Results
Significant treatment–time interactions were found for pain intensity. Compared with the sham group, the NRS and SF-MPQ-2 scores were significantly lower on the seventh day of treatment in the rTMS group (P < 0.001, Cohen’s d = 1.302) (P = 0.003, Cohen’s d = 0.771), and this effect lasted until the third week (P = 0.001, Cohen’s d = 0.860) (P = 0.027, Cohen’s d = 0.550). The HAM-A and HAM-D scores did not change in the rTMS group when compared with the sham group (P = 0.341, Cohen’s d = 0.224) (P = 0.356, Cohen’s d = 0.217). The serum BDNF levels were significantly higher in the treated group (P = 0.048, Cohen’s d = −0.487), and the resting motor threshold (RMT) decreased by 163.65%.
Conclusion
Our findings indicate that rTMS applied over the upper extremity area of the motor cortex can effectively alleviate acute CPSP, possibly by influencing cortical excitability and serum BDNF secretion.
Trial Registration
This trial is registered with Clinical Trial Registry of China: Reg. No. ChiCTR-INR-17012880.
Hinweise
Chen-Guang Zhao and Wei Sun contributed equally to this article as co-first authors.
The original online version of this article was revised to correct the captions for Figures 2 and 3.
Central poststroke pain (CPSP) typically develops within 1 to 6 months after a stroke, and seriously impairs the patient’s quality of life, mood, and social functioning.
Current pharmacological approaches for the treatment of CPSP have failed to provide adequate pain relief.
We aimed to evaluate the analgesic effects of repetitive transcranial magnetic stimulation (rTMS) in patients with acute CPSP.
What was learned from the study?
High-frequency (10 Hz) rTMS applied over the upper extremity area of the motor cortex can effectively alleviate acute CPSP.
rTMS may also relieve depression and anxiety after CPSP.
The analgesic effects of rTMS may be associated with enhanced cortical excitability and increased secretion of brain-derived neurotrophic factor.
Digital Features
This article is published with digital features, including a summary slide, to facilitate understanding of the article. To view digital features for this article go to https://doi.org/10.6084/m9.figshare.14333807.
Anzeige
Introduction
Stroke is one of the most common causes of disability and death among adults [1]. During the rehabilitation phase, some stroke survivors develop central neuropathic pain as a result of the cerebrovascular lesion itself, a syndrome known as central poststroke pain (CPSP). CPSP develops most commonly within 1 to 6 months after a stroke [2‐5], which is also the critical period for functional recovery. CPSP impairs the quality of life, mood, and social functioning of the patient, negatively affecting the rehabilitation process. Even worse, motor function can be impaired by pain; in other words, CPSP can interfere with motor learning capacities and/or motor performance [6]. The incidence of CPSP in stroke patients varies significantly, with a prevalence ranging from 1% to 35.4%, according to published studies [3, 4, 6‐8]. The clinical characteristics of CPSP commonly include allodynia and dysesthesia [9], which can be variously described as a burning, aching, pricking, freezing, squeezing, shooting, or prickling sensation.
Current pharmacological approaches for the treatment of CPSP, including antidepressants, anticonvulsants, and antiepileptics, among others [10‐12], have failed to provide adequate pain relief [13], prompting clinicians to search for possible alternatives. Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive technique involving the application of rapidly changing magnetic fields over an objective encephalic region to influence neural excitability. In this regard, high-frequency rTMS (usually 5–20 Hz) over an objective encephalic region has been recommended for the treatment of CPSP [14, 15], including pain produced by spinal cord injury (SCI), stroke, or multiple sclerosis (MS). The pain reduction ranged between 10% and 40%.
Levels of brain-derived neurotrophic factor (BDNF), a traditional neuronal modulator, have been reported to show a close relationship with neuropathic pain and neuronal plasticity. In a previous study, we showed that serum BDNF levels increased after 3 weeks of high-frequency rTMS in patients with SCI. These findings were in agreement with those of Agnol et al., who reported increased secretion of BDNF after ten sessions of rTMS [16], although others did not find similar changes [17].
Previous studies have focused on the chronic phase of CPSP. However, few studies have evaluated rTMS in patients with acute CPSP. Therefore, we used several questionnaires to assess pain and mood before and after treatment with rTMS. Furthermore, we evaluated whether neurotrophic factor levels and neurophysiological parameters, which have a close relationship with CPSP, were also influenced by rTMS.
Anzeige
Methods
Study Design and Ethical Considerations
This was a prospective, randomized, double-blind, two-group parallel clinical study. It was approved by the Institutional Ethics Committee of Xijing Hospital, Fourth Military Medical University (KY20162079), which adhere to the tenets of the Declaration of Helsinki, and was registered in the Chinese Clinical Trial Registry (Reg. No. ChiCTR-INR-17012880). Patients provided informed consent to participate in the trial. Written informed consent was received from the patients for publication of the data and any accompanying images.
Using the G*Power v.3.1.9.2 statistical tool to achieve a statistical power of 85% with statistical significance at P < 0.05 (two-tailed test) and an effect size of r = 0.4, a minimum sample size of 36 patients was required for the present trial.
A computer random number generator assigned patients to the rTMS or sham group using a block randomization strategy (Fig. 1). Before the recruitment phase, opaque envelopes containing the protocol materials and group allocation were prepared, sealed, and numbered sequentially. After the patient agreed to participate in the trial, the envelope in the sequence was opened by the coordinator, who was not involved with the patient’s intervention.
Fig. 1
CONSORT diagram showing study enrollment
×
All investigators were rehabilitation science majors with more than 3 years of professional experience. To guarantee that the study was performed in a double-blind manner, two independents, specially trained physicians, evaluated the outcome. Participants, as well as those responsible for performing the procedure, were unaware of the group to which the patient had been allocated. Besides rTMS, conventional physical therapy (PT), occupational therapy (OT), and medical treatments (e.g., management of high blood pressure) were also provided to the participants.
Participants
Participants were enrolled consecutively between October 1, 2016, and December 31, 2018, from the inpatient population of the department of rehabilitation of Xijing Hospital.
The inclusion criteria were as follows: (1) first stroke episode, (2) confirmed CPSP diagnosis, sensory disturbance corresponding to the cerebral lesion, (3) admitted ≤ 6 months after stroke onset, (4) ≤ 2 weeks after pain onset [11], (5) age between 30 and 70 years, (6) ability to comprehend instructions (Mini-Mental State Examination score ≥ 22), (7) absence of aphasia, and (8) completion of signed informed consent by the patient or his/her proxy.
The exclusion criteria were as follows: (1) history of seizure, (2) history of craniotomy, (3) implanted stimulator, including pacemakers, or other metallic objects in any part of the body, (4) history of depression or anxiety before stroke, (5) current use of any medications that interfere with rTMS, (5) pain anywhere in the body due to other diseases, or (6) active malignancy or pregnancy.
rTMS Procedure
rTMS was applied with a CCY-1 stimulator (Yiruide Medical Equipment Company, China) using a figure-of-eight coil, following the safety guidelines and protocols for rTMS. Participants were asked to lie comfortably on the examination couch in a quiet room. We determined the resting motor threshold (RMT) as follows: The target muscle was the first dorsal interosseous (FDI) of the hand, contralateral to the infarct. After the skin was prepared, two Ag–AgCl recording surface electromyography electrodes (approximately 1 cm2) were placed on the venter musculi. Electromyography (EMG) signals were filtered, amplified, displayed, and stored in a computer. The RMT was defined as the lowest stimulation intensity capable of eliciting motor-evoked potentials (MEPs) ≥ 50 μV peak-to-peak amplitude in at least five of ten consecutive stimulations (50%). If the RMT in the affected hemisphere (AH) could not be detected, we measured the RMT in the unaffected hemisphere (UH). In the active rTMS stimulation group, rTMS was applied over the motor cortical area (M1) corresponding to the painful zone at a frequency of 10 Hz, as 15 pulse trains (1.5 s), with intertrain intervals of 3 s (total of 1500 pulses) and at an intensity of 80% of the RMT (AH), or 100% (UH) when the RMT could not be detected in the AH. The sham stimulation was delivered using a coil identical to the one in the active group (same shape and color), but with no magnetic stimulation output (only emitting the same sound). Patients in the active rTMS and sham groups received stimulation once a day, 6 days per week, for a total of 3 weeks.
Anzeige
Neuronavigation
We used a neuronavigation system (visor2, ANT Neuro b.v., Enschede, Netherlands) to guide the magnetic stimulation, as described previously [18]. The system generated a three-dimensional reconstruction of the patient’s brain based on magnetic resonance imaging (MRI) data obtained before the first session. An infrared camera allowed the operator to precisely position the coil over the target area under real-time visualization (Fig. 2).
Fig. 2
Neuronavigation-guided rTMS. a Image of rTMS neuronavigation system used on patients with stroke. b Real-time visualization of magnetic coil stimulating the upper extremity area of the M1 cortex
×
Blood Collection and Measurement of Serum BDNF Levels
Blood samples were collected in EDTA-treated tubes (BD, Franklin Lakes, NJ, USA), anonymized, immediately frozen at −20 °C, transported to the key laboratory, and stored at −80 °C until they were subjected to analysis. Serum BDNF concentrations were measured using enzyme-linked immunosorbent assay (ELISA) kits (Multi Sciences, Catalog No. EK11272, lower detection limit = 1.41 pg/ml), according to the manufacturer’s instructions.
Outcome Measurements
Pain intensity was evaluated at different time points: before intervention (T0), and 3 days (T1), 1 week (T2), 2 weeks (T3), and 3 weeks (T4) afterwards. Mood assessments and biochemical and neurophysiological measurements were performed only at T0 and T4. Figure 3 shows the study timetable.
Fig. 3
Schematic diagram of the experimental design. Pain intensity was evaluated by means of NRS and SF-MPQ-2 questionnaires at five different time points: T0 (before treatment), T1 (on the third day), T2 (after 1 week), T3 (after 2 weeks), and T4 (after 3 weeks). Mood changes (HAM-A, HAM-D), neurotrophic factor levels (BDNF), and neurophysiological parameters (RMT, MEP latency, MEP maximal amplitudes) were evaluated only at T0 and T4
×
The primary outcomes were as follows:
1.
Numeric rating scale (NRS). The intensity of pain was measured by the NRS, which consists of an 11-point scale, where 0 indicates no pain and 10 is the worst pain imaginable. The NRS has been recommended by the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) consensus group to measure pain in clinical trials [19].
2.
Short-form McGill Pain Questionnaire-2 (Chinese Edition) (SF-MPQ-2). It includes 20 items that assess four aspects of pain, each item rated on a 0–10 NRS scale [20]. The four subscales have been described before: six items assess continuous pain, six items assess intermittent soreness, six items assess neuropathic pain, and four items assess the affective sphere. Scores on these four aspects were added to obtain the final score. A higher score represents more severe pain.
Anzeige
The secondary outcomes were as follows:
1.
Anxiety was evaluated by means of the Hamilton Anxiety Scale (HAM-A). HAM-A includes 14 items; each item is scored from 0 to 4, with a higher score reflecting more severe anxiety [21].
2.
Depression was assessed by means of the Hamilton Depression Scale (HAM-D) [22, 23]. It consists of 17 items; each item is scored from 0 (not present) to 7 (severe), with a higher total score indicating more severe depression.
3.
Serum BDNF levels.
4.
Neurophysiological parameters, including RMT, MEP amplitude, and MEP latency. We applied single-pulse TMS at 70–85% intensity of the machine export threshold over the affected hemisphere to measure motor cortex excitability. MEP latency and amplitude were calculated based on five waves showing large amplitude and good repeatability. The MEP amplitude is defined as the peak-to-peak amplitude (mV) in the EMG response of the contralateral FDI. The MEP latency is defined as the interval between the start of the single-pulse TMS on M1 and the initiation of the EMG response (ms) in the contralateral target muscle. A TMS-elicited MEP was categorized as present or absent [24‐26].
Statistical Analysis
SPSS software (version 20.0; IBM Corp., Armonk, NY, USA) was used for statistical analysis. The effects of rTMS on pain and mood assessments, as well as on biochemical and neurophysiological parameters, were analyzed by means of repeated-measures analysis of variance (rmANOVA), with time as the within-subjects factor and treatment as the between-subjects factor. Bonferroni adjustment was performed as post hoc analysis for multiple comparisons. A P value less than 0.05 was considered statistically significant. We calculated Cohen’s d and η2 as measures of effect sizes in this study. The interpretation of Cohen’s d and η2 was described in our previous paper [18]. The percentage of change within each individual was calculated as follows: [(Post-rTMS − Pre-rTMS Score)/(Pre-rTMS Score)] × 100.
Results
A total of 40 patients with CPSP were finally enrolled in the study. They were randomly assigned to the rTMS group (n = 20) or the sham group (n = 20). In the sham group, one patient had to abandon the study for family reasons, while another patient with deep vein thrombosis of the lower extremity in the rTMS group dropped out of the trial. The remaining 38 patients completed the 3-week trial. There were no significant differences between the two groups in the mean (SD) age (sham: 48.95 [11.51] VS rTMS 50.16 [11.34], P = 0.746), time since injury (sham: 12.21 [5.01] VS rTMS 10.63 [5.77], P = 0.374), or pain duration (sham: 6.47 [12.57] VS rTMS 6.00 [3.07], P = 0.609). No significant differences were found between the two groups in terms of demographic variables or clinical characteristics (Table 1). Of the 38 participants, three reported short periods of numbness in the scalp or twitching of facial muscles during the rTMS procedure, but no serious adverse effects were observed.
Table 1
Demographic and clinical information of patients
No.
Gender
Age (years)
Time since injury
Pain duration (days)
Type of stroke
Lesion
Pain location
Quality of pain
1
M
30
2 months and 2 weeks
2
I
Right cerebellum
Lower extremity
Freezing, squeezing
2
M
41
2 months
6
H
Left thalamus
Hemibody with face
Aching, pricking
3
M
63
5 months
8
H
Right thalamus
Lower extremity
Numbness, freezing
4
F
61
2 weeks
3
I
Right basal ganglia
Upper extremity
Freezing, pressing
5
M
52
1 month and 2 weeks
5
I
Left thalamus
Hemibody without face
Freezing, squeezing
6
M
68
3 months
6
H
Right thalamus
Lower extremity
Pricking, burning
7
M
56
3 months and 2 weeks
8
H
Left frontal lobe
Upper extremity
Numbness
8
M
59
2 months
10
I
Left thalamus
Upper extremity
Numbness, freezing
9
F
61
2 months
4
H
Left basal ganglia
Hemibody with face
Burning, squeezing
10
M
44
4 months and 2 weeks
5
H
Left external capsule
Upper extremity
Throbbing, tingling
11
F
52
2 months and 2 weeks
7
H
Right external capsule
Hemibody without face
Numbness, tingling
12
M
64
2 months and 3 weeks
2
H
Left cerebellum
Upper extremity
Prickling, numbness
13
M
39
3 months
7
H
Right basal ganglia
Hemibody without face
Shooting, squeezing
14
F
62
4 months
5
H
Left basal ganglia
Upper extremity
Squeezing
15
M
57
3 months
9
I
Right lateral periventricular
Upper extremity
Tingling, prickling
16
F
63
4 months and 2 weeks
4
I
Left lateral periventricular
Hemibody with face
Pricking, squeezing
17
M
48
3 months
6
I
Left basal ganglia
Upper extremity
Tingling, numbness
18
F
44
1 month
2
H
Left basal ganglia
Hemibody
Prickling
19
M
36
2 months and 1 week
7
H
Right basal ganglia
Hemibody with face
Numbness, prickling
20
M
55
1 month and 1 week
11
H
Right external capsule
Upper extremity
Squeezing
21
F
35
2 weeks
12
I
Left lateral periventricular
Hemibody without face
Throbbing, pricking
22
M
34
4 months and 1 week
5
I
Left lateral periventricular
Hemibody without face
Pricking, burning
23
M
47
4 months
9
I
Right thalamus
Upper extremity
Tingling
24
M
35
4 months
6
H
Right frontal lobe
Hemibody
Aching, burning
25
F
53
1 month
2
H
Right thalamus
Hemibody with face
Prickling, burning
26
F
54
2 months
4
H
Right basal ganglia
Lower extremity
Squeezing, burning
27
F
54
2 weeks
5
H
Left frontal lobe
Hemibody without face
Prickling, burning
28
F
70
5 months
7
I
Right basal ganglia
Hemibody without face
Pricking, squeezing
29
F
55
3 months and 2 weeks
9
H
Left basal ganglia
Upper extremity
Pricking, burning
30
F
50
5 months and 1 week
4
I
Left basal ganglia
Upper extremity
Burning
31
F
59
5 months
6
I
Left basal ganglia
Hemibody without face
Freezing, throbbing
32
F
42
10 weeks
10
H
Left thalamus
Upper extremity
Numbness
33
M
31
2 months
12
I
Right frontal lobe
Hemibody with face
Lacerating shooting
34
M
39
2 months and 3 weeks
5
H
Left basal ganglia
Upper extremity
Numbness, lacerating
35
F
33
2 weeks
7
I
Left basal ganglia
Hemibody without face
Squeezing, burning
36
M
58
4 months and 1 week
5
I
Right basal ganglia
Hemibody with face
Burning, shooting
37
F
43
3 months and 2 weeks
9
I
Right basal ganglia
Upper extremity
Tingling, numbness
38
M
36
2 months and 3 weeks
8
H
Left basal ganglia
Upper extremity
Numbness, burning
M male, F female, H hemorrhagic, I ischemic
Primary Outcome
Pain Scores
NRS
The within-subject effects in the rTMS group were significant (P < 0.001 η2 = 0.664). The pain intensity started to decrease on the third day after the intervention (P = 0.073, Cohen’s d = 0.694) and was lowest on the seventh day (P < 0.001, Cohen’s d = 1.906) when compared with baseline. Although the NRS score increased slightly afterwards, the pre-post effects remained significant 3 weeks after the intervention (P < 0.001, Cohen’s d = 1.289). In contrast, there were no significant within-subject effects in the sham group (P = 0.301, η2 = 0.065). The interaction between time and intervention was significant (P < 0.001, η2 = 0.551). The NRS score in the rTMS group was significantly lower than in the sham group on the seventh day (P < 0.001, Cohen’s d = 1.302), and this effect lasted until the third week (P = 0.001, Cohen’s d = 0.860). Pain intensity decreased by 20.29% in the rTMS group and by 0.49% in the sham group (Table 2, Fig. 4a).
Table 2
Treatment outcomes between groups
Treatment
Mean (SD) before treatment (T0)
Mean (SD) after treatment (T4)
Percentage of mean change (T0 to T4)
Cohen’s d (Sham to rTMS at T4)
P value
Primary outcomes
Pain relief after 3 weeks of treatment
Pain scores on NRS
Sham
5.21 (1.03)
5.16 (0.96)
−0.49 (8.25)
rTMS
5.26 (0.99)
4.10 (0.66)
−20.29 (16.19)
0.860
0.001
Pain scores on SF-MPQ2-CN
Sham
42.63 (12.33)
43.53 (11.92)
3.02 (10.26)
rTMS
43.89 (14.48)
33.63 (11.59)
−22.25 (12.74)
0.550
0.027
Secondary outcomes
Mood changes after 3 weeks of treatment
HAM-A
Sham
12.89 (3.38)
12.95 (3.39)
0.86 (9.06)
rTMS
12.58 (3.15)
11.94 (3.08)
−4.93 (7.88)
0.224
0.341
HAM-D
Sham
13.21 (2.94)
12.95 (2.80)
−1.52 (8.59)
rTMS
12.95 (3.12)
12.16 (3.04)
−5.13 (15.18)
0.217
0.356
Biochemical modulator changes after 3 weeks of treatment
Serum BDNF concentrations
Sham
93.47 (26.58)
97.55 (27.63)
4.65 (11.26)
rTMS
93.20 (25.26)
115.14 (22.50)
27.12 (19.19)
−0.487
0.048
Neurophysiological parameter changes after 3 weeks of treatment (N = 15)
MEP threshold
Sham
70.57 (7.00)
65.29 (7.89)
−7.40 (7.67)
rTMS
69.75 (7.53)
56.37 (10.73)
−19.51 (9.21)
0.936
0.094
MEP latency
Sham
25.84 (4.72)
25.01 (4.01)
−2.65 (7.10)
rTMS
26.04 (4.12)
25.09 (3.82)
−3.34 (5.59)
0.019
0.972
MEP maximal amplitude
Sham
320.98 (283.34)
345.74 (287.04)
17.62 (26.13)
rTMS
300.52 (315.80)
366.31 (367.58)
31.26 (33.79)
−0.062
0.907
Fig. 4
Pain relief at different time points in the rTMS and sham groups. a Mean NRS score change in the two groups. b SF-MPQ-2 score change in the two groups. Error bars indicate standard deviation (SD). Asterisks indicate significant pre–post differences (with respect to T0) (*P < 0.05)
×
SF-MPQ-2
Compared with baseline SF-MPQ-2 scores (before intervention), the lowest scores in the rTMS group were observed on the seventh day (P < 0.001, Cohen’s d = 1.674). As time went on, scores increased slightly, but were still significantly lower at the end point (P < 0.001, Cohen’s d = 1.714). In contrast, there were no significant differences in the sham group (P = 0.067, η2 = 0.129). The interaction between time and intervention was significant (P < 0.001, η2 = 0.669). The SF-MPQ-2 scores in the rTMS group were significantly lower than in the sham group on the seventh day (P = 0.003, Cohen’s d = 0.771), after 2 weeks (P = 0.011, Cohen’s d = 0.650), and after 3 weeks (P = 0.027, Cohen’s d = 0.550) (Table 2, Fig. 4b).
Secondary Outcome
All secondary outcomes were measured or recorded before treatment (T0) and on the third week (T4).
Anzeige
Mood Changes: HAM-A and HAM-D
The HAM-A score in the rTMS group showed a significant reduction after 3 weeks of treatment when compared with baseline (P = 0.010, Cohen’s d = 0.661). Similarly, the HAM-D score showed a borderline significant reduction in the rTMS group (P = 0.074, Cohen’s d = 0.435). However, neither score showed any significant differences in the sham group or between groups (Table 2, Fig. 5a, b).
Fig. 5
Mood changes in the rTMS and sham groups at T0 and T4. a Mean HAM-A score changes in the two groups, b HAM-D score changes in the two groups. Error bars indicate standard deviation (SD). Asterisks indicate significant pre-post differences (with respect to T0) (*P < 0.05). A pound sign (#) indicates a borderline significant difference compared with T0 (0.05 < #P < 0.10)
×
Biochemical Changes: Serum BDNF Levels
Serum BDNF levels were significantly higher after 3 weeks of real magnetic stimulation in the rTMS group (P < 0.001, Cohen’s d = −0.619). In contrast, the difference was only borderline significant in the sham group (P = 0.079, Cohen’s d = 0.428). At the end of the intervention, serum BDNF concentrations in the rTMS group (115.14 ± 22.50 pg/ml) were significantly higher than in the sham group (97.55 ± 27.63 pg/ml) (P = 0.048, Cohen’s d = −0.487) (Table 2, Fig. 6).
Fig. 6
Mean serum BDNF concentrations at T0 and T4. Error bars indicate standard deviation (SD). Asterisks indicate significant differences with respect to T0 or between the two groups (*P < 0.05). A pound sign indicates a borderline significant difference compared with T0 (0.05 < #P < 0.10)
×
Changes in Neurophysiological Parameters
RMT
The RMT in both the rTMS and sham groups showed significant pre-post effects after 3 weeks of intervention (P = 0.001, P = 0.041). Intergroup comparison at the end point showed a borderline significant difference between the two groups (P = 0.094, Cohen’s d = 0.936) (Table 2, Fig. 7a).
Fig. 7
Changes in neurophysiological parameters. Mean RMT (a), MEP latency (b), and MEP amplitude (c) were recorded at T0 and T4. Error bars indicate standard deviation (SD). Asterisks indicate significant pre-post differences (with respect to T0) (*P < 0.05). A pound sign indicates a borderline significant difference with respect to T0 or between the two groups (0.05 < #P < 0.10)
×
MEP Latency
Although both the rTMS and sham groups showed a slight reduction in latency after 3 weeks of treatment, the differences were not significant (P = 0.114, P = 0.280, respectively). Similarly, at the end of treatment, the latency values between the two groups did not show any significant difference (P = 0.972, Cohen’s d = 0.019) (Table 2, Fig. 7b).
Maximal MEP Amplitude
The maximal MEP amplitude showed a borderline significant difference after real stimulation (P = 0.064, Cohen’s d = −0.778), but did not change in the sham group (P = 0.154, Cohen’s d = −0.616). Compared with the sham group, the maximal MEP amplitude increased by 77.41% (P = 0.907, Cohen’s d = −0.062) in the rTMS group (Table 2, Fig. 7c).
Discussion
We report here the first study to assess the effects of high-frequency (10 Hz) rTMS over the primary motor cortex in the affected hemisphere of patients with acute CPSP. In terms of primary outcomes, the pain intensity decreased from the first to the third week in the rTMS group, but we did not observe this reduction in the sham group. On the other hand, our results demonstrated that rTMS also reduced the HAM-D and HAM-A scores with respect to baseline. Finally, this analgesic effect of rTMS was accompanied by increased levels of BDNF and enhanced cortical excitability parameters in the third week. To our knowledge, this is the first study to evaluate the effectiveness of high-frequency rTMS in patients with acute CPSP.
The primary outcome of this study was the analgesic effect of rTMS on acute CPSP. We found that patients receiving high-frequency rTMS experienced more pain relief than the sham group. More specifically, high-frequency rTMS (10 Hz), delivered over a total of 2000 pulses to the upper extremity area of M1 at 80% RMT, showed a significant pain-alleviating effect in CPSP patients in the first week that lasted until the third week. Until now, the total number of stimuli delivered in most studies on neuropathic pain has exceeded 1000 pulses. Apparently, more stimuli in one treatment session produced better analgesic effects, according to previous studies [27‐29]. A few studies opted for less stimulation (≤ 1000) as treatment parameter, but the results were controversial. Hosomi et al. demonstrated that 500 stimulations in a session could effectively relieve CPSP [30], but Kang et al. reported only questionable pain reduction after 3 weeks of administering 1000 stimuli per session for 5 consecutive days (total, 5000 stimuli) [31]. Hence, further investigations are needed to determine the optimal parameters for stimulation.
Our previous randomized controlled trial (RCT), which was intended to investigate the analgesic effects of rTMS specifically on neuropathic pain in patients with SCI [18], revealed that 10 Hz rTMS produced transient analgesic effects from the third day to the first week. In the present study, using the same parameters as the previous trial, the pain intensity was lowest on the seventh day, and this analgesic effect lasted until the third week. Although the pain scores increased slightly, this changing trend in the analgesic effect was similar to that reported by others. For example, Kobayashi et al. [32] reported that rTMS once a week for 12 weeks induced sustainable long-term relief of CPSP (61.1% efficacy), although visual analog scale (VAS) scores also rebounded. Future studies are needed to determine whether rTMS has different effects on other types of central nervous system injuries. A slight placebo effect was seen in this study, which was also observed in our previous study. The placebo effect is very common in rTMS studies, and much of the reason is that patients in both groups do not experience exactly the same sensations. Although the coil used in the sham group had the same shape and mimicked the same sound as the real rTMS coil, patients could find differences as the treatment progressed. In this regard, Diefenbach et al. used a sham coil which mimicked the scalp sensations produced by the real rTMS coil [33]. Although this method is far from perfect, it may be the best available technique to use in the sham group.
In this study, we found that real stimulation of M1 improved depression and anxiety in the rTMS group. However, the HAM-D and HAM-A scores did not differ significantly between the two groups at endpoint. A number of possible underlying reasons may account for this: Firstly, depression and anxiety are partly associated with CPSP; since rTMS effectively alleviated pain, the HAM-D and HAM-A scores correspondingly decreased in the rTMS group. Secondly, assessment of depression and anxiety not only measures effects caused by CPSP, but also measures other emotions which may be regulated by the dorsolateral prefrontal cortex (DLPFC), not by M1. Lastly, most patients enrolled in this study (24 out of 28) did not meet the criteria for diagnosis of post-stroke depression (HAM-D > 17), indicating that depressive symptoms in these patients were relatively mild, so depression and anxiety score improvements would not be that obvious.
BDNF is a “classical” neurotrophic factor which has a close relationship with neuronal plasticity and neuropathic pain. We found that serum BDNF levels increased significantly after 3 weeks of rTMS treatment in patients with CPSP, a finding that is in agreement with our previous work and with other studies. In fact, several studies have indicated that serum BDNF levels correlate closely with the analgesic effects of rTMS. Cheeran et al. reported that high BDNF levels can reduce acute pain in healthy male volunteers, a finding along the same line of our results [34]. In this study, we found a negative correlation between serum BDNF levels and pain scores. However, more trials are needed to clarify whether upregulated serum BDNF levels can decrease pain intensity.
Although the mechanisms underlying the analgesic effects of rTMS on M1 are not well known, previous functional magnetic resonance imaging (fMRI) studies have shown that magnetic stimulation of this brain area can regulate the excitability of subcortical and cortical structures related to pain modulation [35]. Although other cortical structures have been targeted, such as DLPFC and the secondary somatosensory cortex (S2) [36, 37], M1 is the area most commonly associated with analgesic effects [13]. There are three main mechanisms which may explain the analgesic effects of rTMS. First, rTMS may improve the excitability of the cerebral cortex, leading to top-down activation of the brainstem and descending inhibition [38]. Second, rTMS may enhance secretion of neurotransmitters such as BDNF and nerve growth factor (NGF). [27]. Third, rTMS may activate emotional and sensory control areas associated with pain [36]. The RMT is an indicator that reflects the excitability of the cerebral cortex and corticospinal tract (CST) [24, 39], as previous pharmacological and physiological studies have demonstrated. In this study, we found a positive correlation between the analgesic effects of rTMS and RMT: as pain intensity decreased, the RMT of the patients at the end of the third week decreased as well, so this could be an important mechanism underlying the analgesic effects of rTMS. On the other hand, MEP is a relatively objective method for evaluating the functionality of the central motor conduction pathways, especially of the corticospinal tract. MEP latency and amplitude serve as indicators, with shorter latencies and larger amplitudes reflecting higher excitability of the motor cortex, and vice versa. Our study found only a borderline significant difference in MEP amplitude in the rTMS group with respect to baseline. However, the MEP latency between the two groups did not differ significantly. These results suggest that MEP latency may be more stable than MEP amplitude, an observation that has been reported previously [40].
The main limitation of our study is the relatively small number of participants. Inadequate sample size may increase the risk of type-II error. Second, we did not classify the participants based on the type of stroke, such as hemorrhagic and ischemic, nor on the affected area. In the future, we would like to evaluate the analgesic effects of rTMS on hemorrhagic versus ischemic stroke, and also conduct subgroup analysis between patients with lesions in the thalamus and other brain areas. Third, it is unknown whether the analgesic effects of rTMS on patients with CPSP are long-lasting, due to lack of follow-up.
Conclusions
Noninvasive, high-frequency (10 Hz) rTMS applied over the affected motor cortex may be an effective way of decreasing the intensity of CPSP in the early stages. rTMS may also relieve depression and anxiety. These effects were transient and may be associated with enhanced cortical excitability and increased secretion of BDNF. Thus, rTMS is a safe and effective adjuvant therapeutic tool for managing the early stages of CPSP. Future investigations using functional near-infrared spectroscopy (fNIRS) and functional magnetic resonance imaging (fMRI) may help clarify the precise mechanisms of action of rTMS.
Acknowledgements
We thank Yuan Shen for the helping in statistical analysis and we also thank all the study participants and their families.
Funding
The study and the journal’s Rapid Service Fee were supported by grants from the National Natural Science Foundation (81100932, 82072534), the Shaanxi Science and Technology Foundation (2021JM-232, 2020KW-050).
Authorship
All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Authors’ Contributions
Conception and design: Hua Yuan, Xiang Mou. Acquisition of data: Chen-Guang Zhao, Wei Sun. Statistical analysis and interpretation of data: Chen-Guang Zhao, Wei Sun, Fen Ju, Shan Jiang, Hong Wang, Xiao-Long. Drafting the article: Chen-Guang Zhao, Wei Sun. Critically revising the article: Hua Yuan, Chen-Guang Zhao, Wei Sun. Reviewed submitted version of manuscript: all authors. Approved the final version of the manuscript on behalf of all authors: Hua Yuan. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis.
Disclosures
Chen-Guang Zhao and Hua Yuan received research grant support from National Natural Science Foundation and Shaanxi Science and Technology Foundation. Hua Yuan is the Director of the Department of Rehabilitation Medicine of Xijing Hospital, Fourth Military Medical University. Wei Sun, Fen Ju, Shan Jiang, Hong Wang, Xiao-Long Sun and Xiang Mou have nothing to disclose.
Compliance with Ethics Guidelines
This work was approved by the Institute Ethics Committee of Xijing Hospital, Fourth Military Medical University (KY20162079). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was received to participate. Written informed consent was received from the patients for the publication of the data. We also received written informed consent from the patients for the photograph included in this paper.
Data Availability
The data sets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.
Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.
Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.
Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
